• Product name

    Anti-PCK1/PEPC antibody [EPR6938]
    See all PCK1/PEPC primary antibodies
  • Description

    Rabbit monoclonal [EPR6938] to PCK1/PEPC
  • Host species

  • Tested applications

    Suitable for: WB, IHC-Pmore details
    Unsuitable for: Flow Cyt,ICC or IP
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Synthetic peptide within Human PCK1/PEPC aa 1-100. The exact sequence is proprietary.

  • Positive control

    • Human fetal kidney lysate; Human adipose tissue lysate; Human liver tissue
  • General notes

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.


     This product was previously labelled as PCK1


    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.



Our Abpromise guarantee covers the use of ab133603 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/10000 - 1/50000. Detects a band of approximately 69 kDa (predicted molecular weight: 69 kDa).
IHC-P 1/100 - 1/250. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
  • Application notes
    Is unsuitable for Flow Cyt,ICC or IP.
  • Target

    • Function

      Catalyzes the conversion of oxaloacetate (OAA) to phosphoenolpyruvate (PEP), the rate-limiting step in the metabolic pathway that produces glucose from lactate and other precursors derived from the citric acid cycle.
    • Tissue specificity

      Major sites of expression are liver, kidney and adipocytes.
    • Pathway

      Carbohydrate biosynthesis; gluconeogenesis.
    • Involvement in disease

      Defects in PCK1 are the cause of cytosolic phosphoenolpyruvate carboxykinase deficiency (cytosolic PEPCK deficiency) [MIM:261680]. PEPCK deficiency is a metabolic disorder resulting from impaired gluconeogenesis. It is a rare disease with less than 10 cases reported in the literature. Clinical characteristics include hypotonia, hepatomegaly, failure to thrive, lactic acidosis and hypoglycemia. Autoposy reveals fatty infiltration of both the liver and kidneys. The disorder is transmitted as an autosomal recessive trait.
    • Sequence similarities

      Belongs to the phosphoenolpyruvate carboxykinase [GTP] family.
    • Post-translational

      Acetylation is increased on addition of glucose and appears to regulate the protein stability.
    • Cellular localization

    • Information by UniProt
    • Database links

    • Alternative names

      • cytosolic [GTP] antibody
      • GTP antibody
      • PCK1 antibody
      • PCKGC_HUMAN antibody
      • PEP carboxykinase antibody
      • PEPCK-C antibody
      • PEPCK1 antibody
      • PEPCKC antibody
      • Phosphoenolpyruvate carboxykinase 1 (soluble) antibody
      • Phosphoenolpyruvate carboxykinase 1 antibody
      • Phosphoenolpyruvate carboxykinase antibody
      • Phosphoenolpyruvate carboxykinase, cytosolic [GTP] antibody
      • Phosphoenolpyruvate carboxykinase, cytosolic antibody
      • Phosphoenolpyruvate carboxylase antibody
      • Phosphopyruvate carboxylase antibody
      see all


    • All lanes : Anti-PCK1/PEPC antibody [EPR6938] (ab133603) at 1/10000 dilution

      Lane 1 : Human fetal kidney tissue lysate
      Lane 2 : Human adipose tissue lysate

      All lanes : Goat anti-Rabbit HRP at 1/2000 dilution

      Predicted band size: 69 kDa
      Observed band size: 69 kDa

    • Immunohistochemical analysis of paraffin-embedded Human liver tissue labelling PCK1/PEPC with ab133603 at 1/100.

    • Equilibrium disassociation constant (KD)
      Learn more about KD

      Click here to learn more about KD


    This product has been referenced in:

    • Bian XL  et al. Nur77 suppresses hepatocellular carcinoma via switching glucose metabolism toward gluconeogenesis through attenuating phosphoenolpyruvate carboxykinase sumoylation. Nat Commun 8:14420 (2017). Read more (PubMed: 28240261) »
    See 1 Publication for this product

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab133603.
    Please use the links above to contact us or submit feedback about this product.

    For licensing inquiries, please contact partnerships@abcam.com

    Sign up